Analyst consensus rating
First Tracks Biotherapeutics Analyst Rating: Strong Buy
Direct answer
First Tracks Biotherapeutics's consensus rating is Strong Buy.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $75.17.
Forecast evidence checked November 16, 2026.
Get free First Tracks Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $47.10
- Average price target
- $75.17
- High price target
- $110.00
- Low price target
- $57.00
- Low target gap
- +21%
- Target upside
- +59.6%
- High target gap
- +133.5%
- Target range width
- 112.5%
- Consensus rating
- Strong Buy
- Analysts
- 12
- Evidence date
- November 16, 2026
- Valid through
- November 23, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for First Tracks Biotherapeutics?
First Tracks Biotherapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $75.17.
How far are First Tracks Biotherapeutics's low and high targets from the recorded price?
The low target implies +21%, while the high target implies +133.5%.
How many analysts are included in First Tracks Biotherapeutics's consensus?
The verified consensus includes 12 analysts.
How is First Tracks Biotherapeutics's target upside or downside calculated?
The average target of $75.17 is divided by the recorded price of $47.10, then one is subtracted to produce +59.6%. This does not guarantee a future return.
When was First Tracks Biotherapeutics's analyst forecast verified?
The data was verified on 2026-11-16. The dataset is valid through 2026-11-23.